Catalyst Dossier · compiled by CeliA 🧫
ABBOTT LABORATORIES (ABT)
Pharmaceutical Preparations · market cap $154.0B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-21
Earnings
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Abbott Laboratories is a diversified U.S. healthcare conglomerate with $44.3B in 2025 revenues spanning medical devices (45%), nutritional products (22%), diagnostics (20%), and ex-U.S. pharmaceuticals (13%). The company carries $27.2B in net debt against $6.8B cash, and its most visible near-term pharmaceutical catalyst is ABT-712 in Phase 3 for Chronic Low Back Pain, with a quarterly earnings report due July 16, 2026.
The catalyst path
- 2026-10-21Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ABT-712 | Phase 3 | Chronic Low Back Pain |
| Zemplar Capsule | Phase 3 | Kidney Disease |
| ABT-263 | Phase 2 | Small Cell Lung Cancer |
| rosuvastatin calcium | Phase 3 | Mixed Dyslipidemia |
| Maxacalcitol | Phase 3 | Chronic Kidney Disease on Hemodialysis |
| ABT-639 | Phase 2 | Diabetic Neuropathic Pain |
| Hydrocodone/Acetaminophen on Extended Release | Phase 3 | Moderate to Severe Chronic, Non-malignant Pain |
| ABT-126 | Phase 2 | Cognitive Deficits in Schizophrenia |
| Extended-Release Hydrocodone/Acetaminophen | Phase 2 | Pain |
| 0.25 mg Atrasentan QD | Phase 2 | Chronic Kidney Disease |
| DB adalimumab 40 mg eow | Phase 3 | Crohn's Disease |
| Clarithromycin | Phase 3 | Acute Bacterial Sinusitis (ABS) |
| adalimumab (Humira) | Phase 3 | Ankylosing Spondylitis |
| Cell-Derived Trivalent Subunit Influenza Vaccine | Phase 2 | Influenza |
| Mitizax | Phase 3 | Allergy |
| Amprenavir/ritonavir | Phase 3 | HIV Infections |
| ABT-874/Human monoclonal antibody against IL-12 | Phase 2 | Multiple Sclerosis |
| verapamil/trandolapril | Phase 3 | Obesity |
| Zemplar (paricalcitol ) capsules | Phase 2 | Diabetic Nephropathy |
| paricalcitol injection (Zemplar) | Phase 2 | Hypocalcemia |
Price & technical context
3-month
+17.2%
6-month
-2.4%
12-month
-23.5%
52-wk range
$82.56–$136.62
vs 50-day MA
-3.0%
vs 200-day MA
-2.0%
Realized vol
26.8%
Max drawdown
-41.1%
Daily closes through 2026-09-21. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ABT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.